06
Jul

On Thursday, a team from Eli Lilly will take the hot seats in front of an advisory committee meeting of external FDA experts to make a case for necitumumab, another cancer drug which offers only marginal efficacy for advanced patients with a troubling profile for potentially lethal adverse events. And their odds-on chance of succeeding helps explain why this field has become so popular with drug developers.

…read more

Source: Eli Lilly preps a familiar case for FDA review of a marginal cancer drug

    

0 No comments